Researchers at the University of Alabama at Birmingham have shown — for the first time — that established lung fibrosis can be reversed using a drug treatment that targets cell metabolism.
This novel finding, reported in the journal Nature Medicine, is important because, despite significant advances to reveal the pathological mechanisms of persistent fibrosis, effective treatment interventions are lacking.
Pulmonary fibrosis can develop after lung injuries like infections, radiation or chemotherapy, or it can have an unknown cause, as in idiopathic pulmonary fibrosis, or IPF. IPF is a progressive, and ultimately fatal, lung disorder that strikes more than 150,000 patients a year in the United States and more than 5 million worldwide.
In experiments using lung tissues from patients with IPF, mouselung fibroblasts and a murine model of lung fibrosis, a team led by Jaroslaw Zmijewski, Ph.D., and Victor Thannickal, M.D., showed the reversal of lung fibrosis and the underlying cellular mechanisms affected by the drug treatment.
Zmijewski and Thannickal are, respectively, associate professor and professor in the UAB Department of Medicine. Zmijewski serves as research director for the Translational Program in ARDS. Thannickal holds the Ben Vaughan Branscomb Chair of Medicine in Respiratory Disease and is director of the UAB Division of Pulmonary, Allergy and Critical Care Medicine.
|Activation of AMPK in myofibroblasts from lungs of humans with IPF, using the drug metformin or another activator called AICAR, led to lower fibrotic activity. AMPK activation also enhanced the production of new mitochondria, the organelles in cells that produce energy, in the myofibroblasts, and it normalized the cells’ sensitivity to apoptosis.|
Interestingly, the drug that accelerated the resolution of lung fibrosis is metformin, which is a safe and widely used agent for non-insulin-dependent diabetes.
The research focused on AMP-activated protein kinase (AMPK), an enzyme that senses energy state in the cell and regulates metabolism. Zmijewski, Thannickal and colleagues found that AMPK activity was lower in myofibroblast cells within fibrotic regions of human lung tissue from IPF patients. Myofibroblasts deposit extracellular collagen fiber as part of the fibrosis process. These myofibroblasts were metabolically active and were resistant to the programmed cell death called apoptosis, a natural process that removes more than 50 billion damaged or aged cells in adults each day.
Activation of AMPK in myofibroblasts from lungs of humans with IPF, using the drug metformin or another activator called AICAR, led to lower fibrotic activity. AMPK activation also enhanced the production of new mitochondria, the organelles in cells that produce energy, in the myofibroblasts, and it normalized the cells’ sensitivity to apoptosis.
Using a mouse model for lung fibrosis elicited by the anti-cancer drug bleomycin, the research team found metformin treatment, starting three weeks after lung injury and continuing for five weeks, accelerated the resolution of well-established fibrosis. Such resolution was not apparent in AMPK-knockout mice, showing that the effect of metformin was AMPK-dependent.
“Together, our studies support the concept that AMPK may function as a critical metabolic switch in promoting resolution of established fibrosis by shifting the balance from anabolic to catabolic metabolism,” the researchers wrote. “Additionally, we provide proof-of-concept that activation of AMPK by metformin or other pharmacologic agents that activate these pro-resolution pathways may be a useful therapeutic strategy for progressive fibrotic disorders.”
Anabolic metabolism builds up molecules in the cell from smaller units, while catabolic metabolism tears larger molecules into smaller pieces.
Learn more: Metformin reverses established lung fibrosis
The Latest on: Pulmonary fibrosis
via Google News
The Latest on: Pulmonary fibrosis
- iBio nabs U.S. patent covering endostatin peptides for fibrosis, shares rise 6%on November 24, 2020 at 10:05 am
The USPTO has issued iBio (NYSEMKT:IBIO), the U.S. Patent No. 10,844,392, entitled “Materials and Methods for Producing Endostatin Fusion Polypeptides in Plant Cells,” which, ...
- Pulmonary Fibrosis Researcher Wins NIH Awardon November 23, 2020 at 7:05 am
PRNewswire/ -- The Pulmonary Fibrosis Foundation (PFF) is announcing that 2019 PFF Scholar, Dr. Jeremy Katzen at the University of Pennsylvania, a PFF ...
- Pipeline Review on Idiopathic Pulmonary Fibrosis - H2 2020 - ResearchAndMarkets.comon November 23, 2020 at 4:33 am
The latest Pharmaceutical and Healthcare disease pipeline guide Idiopathic Pulmonary Fibrosis - Pipeline Review, H2 2020, provides an overview of the Idiopathic Pulmonary Fibrosis (Respiratory) ...
- Basis of Acute Exacerbation of Idiopathic Pulmonary Fibrosis in Japanese Patientson November 20, 2020 at 6:18 pm
A pulmonary perspective by Dr. Collard and colleagues focused on acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF), trying to establish a worldwide consensus about acutely progressive ...
- ‘I’ve had to rephrase some of my songs’ – Irish folk singer reveals how pulmonary fibrosis has affected her singingon November 20, 2020 at 3:03 pm
Irish folk singer Moya Brennan has opened up about how pulmonary fibrosis, a disease which creates scarring on the lungs, has affected her singing.
- 2020 Market Study on the Idiopathic Pulmonary Fibrosis - Opportunity Analysis and Forecasts to 2029 - ResearchAndMarkets.comon November 20, 2020 at 9:42 am
Opportunity Analysis and Forecasts to 2029” report has been added to ResearchAndMarkets.com’s offering. Idiopathic pulmonary fibrosis (IPF) is the most common subtype of idiopathic interstitial ...
- Impact of COVID-19 on the Idiopathic Pulmonary Fibrosis Global Market to 2029on November 18, 2020 at 2:28 am
Opportunity Analysis and Forecasts to 2029" report has been added to ResearchAndMarkets.com's offering. Idiopathic pulmonary fibrosis (IPF) is the most common subtype of idiopathic interstitial ...
- Pulmonary Fibrosis Foundation Launches Campaign To Raise PF Awareness And Early Diagnosison November 12, 2020 at 8:24 am
Disclaimer | Commerce Policy | Made In NYC | Stock quotes by finanzen.net CHICAGO, Nov. 12, 2020 /PRNewswire/ -- The Pulmonary Fibrosis Foundation today announced the "Pinpoint PF" education and ...
- Pulmonary Fibrosis Disease - Global Clinical Trials Review, H2 2020on November 12, 2020 at 5:27 am
New York, Nov. 12, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Pulmonary Fibrosis Disease - Global Clinical Trials Review, H2 2020 ...
via Bing News